Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.
David Cella(Northwestern University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Homa Dastani(Bristol-Myers Squibb (United States)), Bryan Bennett(Adelphi Group (United Kingdom)), Elmer Berghorn(Bristol-Myers Squibb (United States)), Paul Nathan(Mount Vernon Hospital), Fiona Taylor(Adelphi Laboratory Center), Viktor Gruenwald(Medizinische Hochschule Hannover), Michael DeRosa(Adelphi Laboratory Center), Scott Berry(Queen's University), Justin Doan(Bristol-Myers Squibb (United States)), Kristine Broglio(Berry & Associates (United States))
Cited by 4
Related Papers
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Statins for the primary prevention of cardiovascular disease
|Cochrane Database of Systematic Reviews|2013|1.8k